Superficial thrombophlebitis

• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z

Superficial thrombophlebitis

Superficial thrombophlebitis

The goals of treatment are reduction of pain and inflammation, and prevention of complications.

If a catheter or IV line produced the thrombophlebitis, it should be removed.

To reduce discomfort and swelling, support stockings and elevation of the affected extremity are recommended.

Medications to treat superficial thrombophlebitis may include the following:

• Analgesics for pain
• Nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation
• Intravenous anticoagulants followed by oral anticoagulants to reduce the likelihood of clotting

If deeper clots (deep vein thrombosis) are also present, your provider may prescribe thrombolytic drugs to dissolve an existing clot. Antibiotics are prescribed if infection is present.

Surgical removal (phlebectomy), stripping, or sclerotherapy of the affected vein are occasionally needed to treat large varicose veins or to prevent further episodes of thrombophlebitis in predisposed patients.

Superficial thrombophlebitis is usually a benign and short-term condition. Symptoms generally subside in 1 to 2 weeks, but hardness of the vein may remain for much longer.

Complications of superficial thrombophlebitis are rare. Possible problems may include the following:

• Infections (cellulitis)
• Gangrene (tissue death)
• Septic shock
• Deep vein thrombosis
• Pulmonary embolism (often without symptoms)

Call for an appointment with your provider if symptoms indicate superficial thrombophlebitis may be present.

Call your provider if you have been diagnosed with superficial thrombophlebitis and your symptoms do not improve with treatment, or if your symptoms worsen. Call the provider if any new symptoms occur, such as entire limb becoming pale, cold, or swollen, or if chills and fever develop.

Review Date: 09/11/2006
Reviewed By: Corey Cutler, MD, MPH, FRCP(C), Assistant Professor of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Review provided by VeriMed Healthcare Network.